

The Effect of the Dental Stem Cell Secretome on Tissue Regeneration: A Systematic Review

Nusaibah Sakinah Nordin^{1,2}, Maryati Md Dasor², Farha Ariffin², Zurairah Berahim¹, Muhammad Huzaimi Haron^{3,*}



Use your smartphone to scan this QR code and download this article

ABSTRACT

Secretome therapy is a promising approach in tissue regeneration because it can reproduce most of the advantages of cell-based therapies. This review aims to investigate the most prominent effect of using dental-derived secretome on tissue regeneration using a systematic review approach. A systematic electronic search was conducted via the PubMed, Scopus and Wiley online library databases for studies published in English up to October 2020. All the articles from the databases were screened, and the criteria for inclusion and exclusion were applied. Forty papers were included in the study, whereby there were 16 *in vitro* studies and 11 *in vivo* studies with different animal models. No clinical trial has been reported yet. The most studied DSCs were human SHEDs (12 studies), followed by human DPSCs (11) and human PDLSCs (5). The majority of the studies used secretome from human SHEDs and DPSCs. TGF- β 1 is the most frequently detected protein in the secretome, which comes from six types of DSCs, followed by NGF and NT-3, which were found in five different types of DSC secretome. The compositions of the secretome were found to promote the regeneration of the tissues through their neurogenic, angiogenic, osteogenic and odontogenic effects, with the majority of studies reviewed reporting using them for non-dental tissue regeneration. From this review, DSC-CM reported favorable tissue regeneration potential; however, many factors need to be explored in future research with regard to the application of secretome delivery, particularly DSC-CM, in the clinical setting.

Key words: dental-derived secretomes, paracrine mediated therapy, tissue regeneration

¹School of Dental Sciences, Universiti Sains Malaysia

²Faculty of Dentistry, Universiti Teknologi MARA

³Faculty of Medicine, Universiti Teknologi MARA

Correspondence

Muhammad Huzaimi Haron, Faculty of Medicine, Universiti Teknologi MARA

Email: drhuzaimi@uitm.edu.my

History

- Received: Jul 30, 2022
- Accepted: Sep 26, 2022
- Published: Nov 14, 2022

DOI : 10.15419/psc.v9i1-2.413



Copyright

© Biomedpress. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.



INTRODUCTION

In regenerative medicine, tissue engineering has arisen as a promising approach for the restoration, repair and healing of organ and tissue functions, especially in tissues susceptible to disease, injury, and degeneration. At present, tissue engineering studies are focused on adult mesenchymal stem cells, which have become among the most frequently explored types of cells in this field¹. Mesenchymal stem cells (MSCs) are undifferentiated multipotent cells that possess self-renewal capabilities and can differentiate into various mesoderm cell lineages, such as osteogenic, adipogenic and chondrogenic lines. Aside from bone marrow and adipose tissue, cells possessing stem cell characteristics have also been successfully isolated from different parts of the tooth. These isolated cells are known as dental stem cells and include dental pulp stem cells (DPSCs)^{2,3}, stem cells from exfoliated deciduous teeth (SHED)⁴, periodontal ligament stem cells (PDLSCs)⁵, stem cells from apical papilla (SCAP)^{6,7}, dental follicle progenitor cells (DFCs)⁸ and gingival tissues derived from mesenchymal stem cells (GMSCs)^{9,10}.

The majority of dental-derived stem cells (DSCs) can be obtained from human exfoliated deciduous teeth and orthodontically extracted premolars and third molars. These sources of stem cells are considered biological waste in dentistry despite containing multipotent stem cells^{4,11}. Premolars are the most common teeth indicated for extraction in orthodontics and are often ideal for the relief of anterior and posterior crowding. However, the decision of extracting between the first or second premolars depends on several factors, including the anchorage requirement, the severity of crowding, and the amount of overbite and overjet¹². Extraction of the third molar for orthodontic reasons is rare, as both orthodontists and oral surgeons must make appropriate decisions and consider the potential risks and benefits of the procedure specifically pertaining to the surgical removal of asymptomatic impacted third molars¹³. There are several orthodontic reasons for the extraction of third molars that aim to prevent late mandibular incisor crowding¹⁴, to allow molar distalization¹⁵ and to prepare for orthognathic surgery¹⁶. Experimental research using stem cells showed that they produce reliable and effective tissue regenera-

Cite this article : Nordin N S, Dasor M M, Ari in F, Berahim Z, Haron M H. **The Effect of the Dental Stem Cell Secretome on Tissue Regeneration: A Systematic Review.** *Progress Stem Cel.*; 2022, 9(1-2):318-336.

tion. However, there are several shortcomings in terms of the clinical application of therapy using MSCs¹⁷: (i) the host immune response might cause rejection of transplanted MSCs in the long term, (ii) there could be an imbalance and disturbance in the homeostasis of local tissue, (iii) the risk for tumor formation may increase due to long-term *ex vivo* expansion and/or due to immunosuppression of the local tissue, and (iv) the chances for ectopic tissue formation by the transplanted MSCs become higher¹³.

To overcome these drawbacks of using MSCs, an increasing number of studies have reported the use of the MSC secretome¹⁸. Secretome are various cellular products, such as cytokines, growth factors and enzymes secreted by MSCs^{19,20}. These biologically active chemical products play significant roles in diverse aspects of tissue function, repair and homeostasis^{21,22}. The function of the secretome is to suppress immune responses²³, reduce oxidative stress¹³, stimulate angiogenesis²⁴, and induce the recruitment, proliferation and differentiation of endogenous stem cells²⁵. Secretome are easily obtained via *in vitro* culture of various cells, where they are contained or extracted from the culture media, often referred to as conditioned media (CM). In various studies, CM from stem cells has shown promising results in regenerative medicine and tissue engineering²⁶, including CM from SHED and CM from healthy and inflamed periodontal tissue^{27,28}.

When compared to stem cell therapy, secretome therapy offers potential benefits because it can reproduce most of the advantages of cell-based therapies with minimal side effects. Furthermore, using the secretome as therapy provides many practical advantages, such as ease of preservation, sterilization, and packaging¹. Apart from that, they also have an extended duration of storage without losing their properties^{29,30}, ease in gauging proper dosages and can be produced in mass²⁰ as well as a noninvasive extraction procedure that may save both time and cost of production²⁴. Despite the potential benefits of the secretome, the effect of the dental-derived secretome on specific types of tissue has not been systematically reviewed. The focus question is to systematically review *in vitro*, *in vivo* and clinical studies on the effect of the dental-derived secretome in terms of tissue regeneration potential. Thus, we aim to identify the most prominent effect of using a dental-derived secretome on tissue regeneration using a systematic review approach.

METHODS

The Preferred Reporting Items for Systematic Review (PRISMA) checklist was used as a guideline in conducting this review³¹. A comprehensive and systematic electronic search of MEDLINE via PubMed, Scopus and Wiley online library databases was conducted for studies published in English up to October 2020 (Figure 1).

Study design

This study systematically reviewed and summarized all the published studies regarding the use of dental stem cell-derived conditioned media in tissue regeneration by searching electronic databases.

Inclusion criteria

The included studies were *in vivo*, *in vitro* and clinical studies on the dental stem cell secretome and tissue regeneration. Language was limited to English, and no manual or gray literature search was included.

Exclusion criteria


All studies on embryonic stem cells, bone marrow stem cells, induced pluripotent stem cells, other types of mesenchymal stem cells, cell therapy, secretome derived from ameloblasts, odontoblasts, dental epithelium, narrative reviews, systematic reviews and/or meta-analyses.

Information sources and search strategies

A comprehensive search of online databases was implemented through MEDLINE via PubMed, SCOPUS and Wiley Online Library. All studies published up to October 2020 were included. A Boolean operator was used for the search strategy by combining terms and free text words: “dental stem cells” AND secretome, “dental secretome” OR “paracrine therapy” AND regeneration, “dental stem cells” AND “conditioned medium” AND regeneration, dental AND “paracrine mediated therapy”. Then, all duplicate papers were removed by the reference manager software (Mendeley).

Study selection

The data were extracted independently by four authors (N.S. N, M.M. D, F. and M.H. with an extraction form specifically designed for this study. Then, any disagreement on the data extracted was resolved through discussion and mutual consensus between the authors. Interrater reliabilities were calculated using Cohen's Kappa ($\kappa = 0.704$, which indicates substantial agreement).



Data collection process

For data collection, necessary information was extracted as follows: the characteristics of the study (authors, year of publication, country of the study conducted), type of study design (*in vitro*, *in vivo*, clinical studies), source of dental stem cell secretome, test for dental stem cell markers, test and growth factors identified from the secretome, test and analysis for regeneration with the findings, clinical test used, and any biomaterials used for regeneration.

RESULTS

Study overview

A total of 40 studies were selected after thorough screening by the authors, as listed in **Table 1**. Of these, 16 are *in vitro* studies, and 11 are *in vivo* studies with various types of animal models. The remaining 13 studies were combinations of *in vitro* and *in vivo* intervention studies. There were no clinical trials reported. Nine studies were excluded because the studies used CM from Hertwig's epithelial root sheath (HERS) (2),

study on genetically modified dental stem cells (1), study on differentiated human dental pulp (1), regeneration studies done using stem cells not the CM (3), not a tissue regeneration study (1), and insufficient information (1).

The source of dental-derived stem cell secretome is from either humans or animals. There were 29 studies that used human dental stem cells as the source of the conditioned media, while nine studies used animal dental stem cells, such as stem cells from rats, pigs and dogs. One study used both dental stem cells from humans and porcines, whereby they utilized tooth germ cells. Another study did not specify the source of tooth germ cells used.

The source of the secretome used in all the studies varies from dental pulp stem cells (DPSCs), human exfoliated deciduous teeth (SHEDs), stem cells from apical papilla (SCAPs), dental follicle stem cells (DFSCs), periodontal ligament stem cells (PDLSCs), gingival mesenchymal cells (GCMs) and tooth germ cells (TGCs). TGCs can be further subcategorized into apical tooth germ cells (APTGCs), embryonic tooth

Table 1: Summary of studies selected

| Year (Location) | Study setting | Secretome cellular source (Organism) | Stem cell marker reported (Technique) | Secretome proteomic analysis (Technique) | Effects (details) | | | | | Reference |
|-----------------|-----------------------------|--------------------------------------|---------------------------------------|--|-------------------|------------|------------|-------------|--|-----------|
| | | | | | Angiogenic | Neurogenic | Osteogenic | Odontogenic | Others | |
| 2009 (China) | <i>In vitro and in vivo</i> | APTGC (rat) | Yes (FC) | No | | | | | x (cementogenic) | 32 |
| 2010 (USA) | <i>In vitro</i> | DPSC (human) | No | No | | | | x | | 33 |
| 2010 (China) | <i>In vitro and in vivo</i> | ETGC (rat) | No | No | x | | | x | | 34 |
| 2011 (China) | <i>In vitro</i> | DFC (rat) | No | No | x | | | | | 35 |
| 2011 (China) | <i>In vitro and in vivo</i> | TGC (human and porcine) | No | No | | | | x | | 36 |
| 2013 (Japan) | <i>In vitro</i> | DPSC (human) | Yes (FC) | No | | | | | x (anti-inflammatory, anti-apoptotic) | 37 |
| 2014 (China) | <i>In vitro</i> | DFC (rat) | No | No | x | | | | | 38 |
| 2015 (Japan) | <i>In vitro and in vivo</i> | DPSC (porcine) | No (referred previous work) | Yes (WB) | | | | x | | 39 |
| 2015 (Japan) | <i>In vivo</i> | SHED (human) | Yes (FC) | Yes (multiplex assay) | | | | | x (anti-apoptosis, anti-inflammatory) | 40 |

Continued on next page

| Table 1 continued | | | | | | | | | | |
|-------------------|-----------------------------|--------------------------------------|---------------------------------------|--|-------------------|------------|------------|-------------|------------------------------------|--------------------|
| Year (Location) | Study setting | Secretome cellular source (Organism) | Stem cell marker reported (Technique) | Secretome proteomic analysis (Technique) | Effects (details) | | | | | Reference |
| | | | | | Angiogenic | Neurogenic | Osteogenic | Odontogenic | Others | |
| 2015 (Japan) | <i>In vivo</i> | SHED (human) | No | Yes (WB) | | | | | x (anti-inflammatory) | 41 |
| 2015 (Japan) | <i>In vitro</i> | DPSC (dog) | Yes (FC) | No | x | x | x | | x (anti-apoptotic, chemotactic) | 42 |
| 2015 (Japan) | <i>In vitro and in vivo</i> | SHED (human) | No | Yes (ELISA) | x | x | | | | 43 |
| 2015 (Japan) | <i>In vitro and in vivo</i> | SHED (human) | No | No | | | | | x (anti-inflammatory) | 40 |
| 2016 (Japan) | <i>In vitro and in vivo</i> | DPSC (porcine) | No | No | x | | | x | | 44 |
| 2016 (Japan) | <i>In vivo</i> | PDLSC (human) | No | Yes (LC/MS) | | | x | | | 45 |
| 2016 (Japan) | <i>In vitro</i> | DPSC (human) | No | No | | x | | | x (chemotactic, proliferative) | 46 |
| 2017 (Norway) | <i>In vitro and in vivo</i> | DPSC (human; normoxic and hypoxic) | No (referred previous work) | Yes (ELISA) | x | | x | | | 47 |

Continued on next page

Table 1 continued

| Year (Location) | Study setting | Secretome cellular source (Organism) | Stem cell marker reported (Technique) | Secretome proteomic analysis (Technique) | Effects (details) | | | | | Reference |
|-----------------|-----------------------------|--------------------------------------|---------------------------------------|--|-------------------|------------|------------|-------------|---|--------------------|
| | | | | | Angiogenic | Neurogenic | Osteogenic | Odontogenic | Others | |
| 2017 (Italy) | <i>In vitro and in vivo</i> | PDLSC (human; hypoxic) | No | Yes (WB) | | | | | x (anti-inflammatory) | 48 |
| 2017 (Japan) | <i>In vivo</i> | SHED (human) | No (referred previous work) | Yes (ELISA) | x | x | | | x (anti-inflammatory) | 49 |
| 2017 (Sweden) | <i>In vitro and in vivo</i> | SCAP, DPSC, PDLSC (all human) | Yes (FC) | Yes (ELISA) | | x | | | | 50 |
| 2017 (India) | <i>In vitro</i> | SCAP, DPSC, DFC (all human) | Yes (FC) | Yes (multiplex ELISA) | | x | | | | 51 |
| 2017 (Japan) | <i>In vitro</i> | DPSC (human) | Yes (FC) | No | | x | | | x (chemotactic, anti-inflammatory, anti-apoptosis) | 52 |
| 2017 (Italy) | <i>In vitro</i> | GMSC (human) | Yes (FC) | Yes (WB) | | x | | | x (anti-inflammatory) | 53 |

Continued on next page

| Table 1 continued | | | | | | | | | | |
|-------------------|-----------------------------|--------------------------------------|---------------------------------------|--|-------------------|----------------------|------------|-------------|-----------------------|-----------|
| Year (Location) | Study setting | Secretome cellular source (Organism) | Stem cell marker reported (Technique) | Secretome proteomic analysis (Technique) | Effects (details) | | | | | Reference |
| | | | | | Angiogenic | Neurogenic | Osteogenic | Odontogenic | Others | |
| 2018 (Norway) | <i>In vitro</i> | DPSC (human) | No (referred previous work) | Yes (ELISA) | x | | | | | 54 |
| 2018 (Japan) | <i>In vivo</i> | SHED (human) | No | No | | x | | | | 55 |
| 2019 (Taiwan) | <i>In vivo</i> | DPSC (rat) | Yes (FC) | Yes (multiplex ELISA) | | | | | x (anti-inflammatory) | 56 |
| 2019 (Brazil) | <i>In vitro and in vivo</i> | SHED (human) | Yes (FC) | Yes (ELISA) | x | | | x | x (wound closure) | 57 |
| 2019 (Belgium) | <i>In vitro</i> | DPSC (human) | No (referred previous work) | No | | x | | | x (cell migration) | 58 |
| 2019 (Japan) | <i>In vitro and in vivo</i> | SHED (human) | No | Yes (ELISA) | | x | | | | 59 |
| 2020 (Iran) | <i>In vitro</i> | PDLSC (human) | Yes (FC) | No | | | | | x (SC proliferation) | 60 |
| 2020 (Taiwan) | <i>In vivo</i> | SHED (human) | No | Yes (multiplex ELISA) | | x (neuro-protective) | | | x (anti-inflammatory) | 61 |

Continued on next page

Table 1 continued

| Year (Location) | Study setting | Secretome cellular source (Organism) | Stem cell marker reported (Technique) | Secretome proteomic analysis (Technique) | Effects (details) | | | | | Reference |
|-----------------|-----------------------------|--------------------------------------|---------------------------------------|--|-------------------|------------|---------------------------|-------------|---------------------------------------|--------------------|
| | | | | | Angiogenic | Neurogenic | Osteogenic | Odontogenic | Others | |
| 2020 (Japan) | <i>In vivo</i> | SHED (human) | No | Yes (multiplex assay) | | | x | | | 62 |
| 2020 (China) | <i>In vitro and in vivo</i> | DFSC (rat) | Yes (FC) | No | | | | x | x (anti-apoptotic, anti-inflammatory) | 63 |
| 2020 (Belgium) | <i>In vitro</i> | DPSC (human) | No | No | | | | | x (chondrogenic) | 11 |
| 2020 (Malaysia) | <i>In vitro</i> | SHED (human) | Yes (FC) | Yes (ELISA) | | | | | x (anti-inflammatory, chondrogenic) | 64 |
| 2020 (Japan) | <i>In vivo</i> | SHED (human) | No | Yes (LC/MS) | | | x (osteoclast inhibition) | | x (anti-apoptotic, anti-inflammatory) | 65 |
| 2020 (China) | <i>In vivo</i> | GMSC, PDLSC (both human) | Yes (FC) | No | | | x | | | 66 |
| 2020 (Japan) | <i>In vivo</i> | DPSC (human) | No | No | | | | | x (cell proliferation) | 67 |
| 2020 (China) | <i>In vitro</i> | SCAP (human) | No | Yes (WB) | | | x | x | | 68 |

Continued on next page

| Table 1 continued | | | | | | | | | | |
|-------------------|---------------|--------------------------------------|---------------------------------------|--|-------------------|------------|------------|-------------|--------|-----------|
| Year (Location) | Study setting | Secretome cellular source (Organism) | Stem cell marker reported (Technique) | Secretome proteomic analysis (Technique) | Effects (details) | | | | | Reference |
| | | | | | Angiogenic | Neurogenic | Osteogenic | Odontogenic | Others | |
| 2019 (China) | In vitro | TGC (unknown organism) | No | No | | | x | x | | 69 |

ELISA: enzyme-linked immunosorbent assay; FC: flow cytometry; WB: Western blot

germ cells (ETGCs) and neonatal tooth germ cells (NTGCs). Human SHEDs are the most studied DSCs (12 studies), followed by human DPSCs (11) and human PDLSCs (5). Secretome from human SHEDs and DPSCs contributed to the majority of the studies.

To ensure that the secretome obtained is of stem cell origin, most studies would need to show the presence of stem cell markers on the cells used. However, from this review, there were only 18 studies reporting on stem cell markers, whereas the remaining studies did not. Among studies that reported stem cell markers, 15 used flow cytometry, while the remaining studies did not state the technique used.

Proteomic analysis of the DSC secretome

Sixteen studies reported proteomic analysis of CM. The techniques used in identifying the secreted factors from the DSCs are ELISA (8 studies), Western blot (1), multiplex analysis (5) and liquid chromatography tandem mass spectrometry (LC-MS/MS) (2). The most frequently detected protein is transforming growth factor- β 1 (TGF- β 1), which is present in the secretome of six types of DSCs: human SHEDs, SCAPs, DPSCs, DFCs, and GMSCs as well as rat DPSCs. This was followed by nerve growth factor (NGF) and neurotrophin-3 (NT-3), which were found in five different types of DSC secretome. Brain-derived neurotrophic factor (BDNF), tissue inhibitor of metalloproteinase-1 (TIMP-1) and vascular endothelial growth factor (VEGF) were detected in the secretome from four different sets of DSCs. Further details of the proteins detected in the DSC secretome are presented in **Table 2**.

Table 2: List of frequently reported protein contents of the DSC secretome

| Protein | Source of secretome | Reference |
|----------------|---------------------|--|
| TGF- β 1 | Human SHEDs (2) | Muhammad et al 2020 ⁶⁴ , Chen et al 2020 ⁶¹ |
| | Human SCAPs (1) | Kumar et al 2016 ⁵¹ |
| | Human DPSCs (1) | Kumar et al 2016 ⁵¹ |
| | Human DFCs (1) | Kumar et al 2016 ⁵¹ |
| | Human GMSCs (1) | Rajan et al 2017 ⁵³ |
| | Rat DPSCs (1) | Chen et al 2019 ⁵⁶ |
| NGF | Human SHEDs (2) | Miura-Yura et al 2019 ⁵⁹ , Sugimura et al 2015, ⁴³ |
| | Human SCAPs (1) | Kumar et al 2016 ⁵¹ |
| | Human DPSCs (1) | Kumar et al 2016 ⁵¹ |
| | Human DFCs (1) | Kumar et al 2016 ⁵¹ |
| | Human GMSCs (1) | Rajan et al 2017 ⁵³ |
| NT-3 | Human SHEDs (2) | Sugimura et al 2015, ⁴³ Hiraki et al, 2020 ⁶² |
| | Human SCAPs (1) | Kumar et al 2016 ⁵¹ |
| | Human DPSCs (1) | Kumar et al 2016 ⁵¹ |
| | Human DFCs (1) | Kumar et al 2016 ⁵¹ |
| | Human GMSCs (1) | Rajan et al 2017 ⁵³ |
| BDNF | Human SCAPs (2) | Kolar et al 2017 ⁵⁰ , Kumar et al 2016 ⁵¹ |
| | Human DPSCs (2) | Kolar et al 2017 ⁵⁰ , Kumar et al 2016 ⁵¹ |
| | Human SHEDs (3) | Miura-Yura et al 2019 ⁵⁹ , Sugimura et al 2015, ⁴³ Hiraki et al 2020 ⁶² |
| | Human DFCs (1) | Kumar et al 2016 ⁵¹ |
| TIMP_1 | Human DPSCs (1) | Gharai et al 2018 ⁵⁴ |
| | Human SHEDs (2) | Chen et al 2020 ⁶¹ , Hiraki et al 2020 ⁶² |
| | Human PDLSCs (1) | Nagata 2016 ⁴⁵ |
| | Rat DPSCs (1) | Chen et al 2019 ⁵⁶ |

Continued on next page

Table 2 continued

| Protein | Source of secretome | Reference |
|---------------|--|--|
| VEGF | Human SHEDs (4) Human DPSCs (3) Human SCAPs, (1) Human PDLSCs (2) | de Cara et al 2019 ⁵⁷ , Miura-Yura et al 2019 ⁵⁹ , Sugimura et al 2015, ⁴³ Hiraki et al, 2020 ⁶² Gharraei et al 2018 ⁵⁴ , Kolar et al, 2017, Fujio et al 2015 ⁴⁷ Kolar et al 2017 ⁵⁰ Kolar et al 2017 ⁵⁰ , Nagata, 2016 ⁴⁵ |
| GCSF | Human SCAPs (1) Human DPSCs (1) Human DFCs (1) | Kumar et al 2016 ⁵¹ Kumar et al 2016 ⁵¹ Kumar et al 2016 ⁵¹ |
| IFN-gamma | Human SCAPs (1) Human DPSCs (1) Human DFCs (1) | Kumar et al 2016 ⁵¹ Kumar et al 2016 ⁵¹ Kumar et al 2016 ⁵¹ |
| IGF_BP2 | Human DPSCs (1) Human SHEDs (1) Human PDLSCs (1) | Gharraei et al 2018 ⁵⁴ Chen et al, 2020 ⁶¹ Nagata, 2016 ⁴⁵ |
| IGF-BP3 | Human DPSCs (1) Human SHEDs (1) | Gharraei et al 2018 ⁵⁴ Chen et al, 2020 ⁶¹ |
| TIMP-2 | Rat DPSCs (1) Human SHEDs (1) | Chen et al, 2019 ⁵⁶ Chen et al, 2020 ⁶¹ |
| Angiopontin-2 | Human DPSCs (1) | Fujio et al 2015 ⁴⁷ |
| BMP-2 | Human SHEDs (1) | Hiraki et al, 2020 ⁶² |
| BMP-4 | Human SHEDs (1) | Hiraki et al, 2020 ⁶² |
| BMP-5 | Human SHEDs (1) | Chen et al, 2020 ⁶¹ |
| CNTF | Human SHEDs (1) | Sugimura et al 2015 ⁴³ |
| FGF-2 | Human SHEDs (2) | Miura-Yura et al 2019 ⁵⁹ , Hiraki et al, 2020 ⁶² |
| GDNF | Human SHEDs (2) | Sugimura et al 2015, ⁴³ Hiraki et al, 2020 ⁶² |
| HGF | Human SHEDs (2) | Sugimura et al 2015, ⁴³ Hiraki et al, 2020 ⁶² |
| IGF-1 | Rat DPSCs (1) | Chen et al, 2019 ⁵⁶ |
| IGF-BP4 | Human SHEDs (1) | Chen et al, 2020 ⁶¹ |

Continued on next page

Table 2 continued

| Protein | Source of secretome | Reference |
|---------|---------------------|--|
| IGF-BP6 | Human SHEDs (1) | Chen et al, 2020 ⁶¹ |
| | Human PDLSCs (1) | Nagata, 2016 ⁴⁵ |
| IL-10 | Human SHEDs (1) | Muhammad et al 2020 ⁶⁴ |
| | Human GMSCs (1) | Rajan et al, 2017 ⁵³ |
| IL-6 | Human SHEDs (1) | Muhammad et al 2020 ⁶⁴ |
| MCP-1 | Human SHEDs (2) | Kano et al 2016 ⁴⁹ , Hiraki et al, 2020 ⁶² |
| | Human PDLSCs (1) | Nagata, 2016 ⁴⁵ |
| PAI-1 | Human DPSCs (1) | Gharaei et al 2018 ⁵⁴ |
| PDGFR-B | Human PDLSCs (1) | Nagata, 2016 ⁴⁵ |
| SDF-1 | Human DPSCs (1) | Gharaei et al 2018 ⁵⁴ |

Functional analysis using the DSC secretome

Overview

Despite using DSCs to obtain the secretome, the majority of studies we reviewed reported using the cells for nondental applications, with neuroregeneration being the most frequently studied (12 out of 40 studies). Others include regeneration of bone tissue, blood vessels, salivary duct, lung, and liver. Among the studies reporting using secretome for dental tissue regeneration (15 studies), three areas were examined: (i) dental pulp, (ii) periodontal, and (iii) dentin. The effects of the secretome are summarized below.

Neurogenic effects

Among studies reporting favorable neurogenic effects (total of 15), all but two used the DSC secretome obtained from humans instead of animal cells. Most of the studies using the human DSC secretome were sourced from SHED, followed by secretome from DPSCs, PDLSCs, SCAP, and GMSCs. When looking from the experimental design perspective, most of the neurogenic studies were performed in both cell culture and animal models of various neurodegenerative diseases (such as hemorrhagic stroke, Alzheimer's disease or diabetic neuropathy), with only six studies reporting the effects of cell culture experiments exclusively. The most frequently reported *in vitro* finding is enhanced neurite outgrowth, followed by increased neuronal proliferation. Three out of eight studies reporting neurite outgrowth also reported increased expression of BDNF with secretome treatment.

Angiogenic effects

Most of the data on the angiogenic effects of the DSC secretome were obtained from work on human umbilical vein endothelial cells (HUVECs), with only one from human dermal microvascular endothelial cells. From a total of nine studies, four of them reported only *in vitro* findings, whereas the remainder also reported effects in animal models. The secretome were obtained from either DPSCs (6 studies; 4 of which were human cells) or SHED (all 3 from humans). Looking at the *in vitro* studies, five of them reported enhanced vascular network formation, three studies reported increased cell proliferation/viability, while two reported observing HUVECs differentiating into VE-cadherin-positive endothelial cells.

Osteogenic/odontogenic effects

Odontogenic effects are seen when cellular differentiation indicates that the formation of odontoblasts is

imminent. Odontoblasts are cells that lay down the dentin layer during tooth formation and are usually found in the dental pulp. During *in vitro* experimentation, Alizarin red staining used to detect intracellular mineralization was used to detect odontogenic or osteogenic processes. In our review, we found 12 studies looking at the osteogenic/odontogenic effects of the secretome, of which only four were sourced from humans, while the rest were obtained from rats and pigs. There were multiple cell types from which the secretome were obtained, with TGCs being the most used (in four studies), followed by DPSCs, DFSCs (three each), SCAP and SHED. In determining the osteogenic/odontogenic effects of the secretome, the parameters reported were enhanced intracellular mineralization (6 studies), increased expression of mineralization markers such as ALP, BSP and CAP (5), and increased odontoblastic differentiation (4). The single study that used the SHED secretome reported inhibition of osteoclastic activity *in vitro*, which was reflected as a reduction in bone resorption under radiography *in vivo*.

DISCUSSION

Most of the studies reviewed here were preclinical *in vitro* and animal studies reporting possible mechanisms of secretome effects, which can be grouped into neurogenic, angiogenic, osteogenic and odontogenic. When compared to the list of proteins detected in the secretome, a correlation can be observed between the type of protein found and the effects seen. As an example, TGF- β 1 is a mediator of osteogenic differentiation and was repeatedly reported to be a component of secretome from various DSCs. Furthermore, NGF, NT-3 and BDNF are well-known neurotrophic factors⁷⁰⁻⁷² that correlate with the neuroregenerative effects seen in a large proportion of the studies here. While there are various sources of the DSC secretome, those obtained from the culture of DSCs acquired from permanent teeth (such as DPSCs and PDLSCs) as well as deciduous teeth (called SHEDs) were mostly reported. This is well explained by the fact that such cells are the most easily accessible for the isolation of stem cells⁷³. However, not all studies confirmed their claim that the cells they used are stem cells, as only 19 studies reported performing stem cell marker analysis. Other studies that did not report performing this analysis referred to previous publications in their methodology sections. This step is crucial, as it confirmed the stemness of the cells obtained from the various intraoral sources⁷⁴.

At present, clinical studies reporting the effectiveness of the DSC secretome in clinical tissue regeneration

are still absent. Until June 2021, there were only three ongoing clinical trials using the MSC secretome registered with the US National Institute of Health (<https://clinicaltrials.gov>), with the secretome used in all three studies reported to be from bone marrow MSCs. This could be due to a number of reasons. First, the potential of the DSC secretome to instigate an adverse reaction may not have been well studied. This is reflected in an article search on Scopus using the terms “secretome OR (conditioned media)” AND “toxic*”, which returned a result set that was overwhelmingly positive in nature. While this is encouraging, the lack of reports on the propensity of the secretome to cause any adverse biological response will hinder their clinical translation, as the content of the secretome varies and is likely to be antigenic in nature when administered⁷⁵.

Hence, the important nonclinical studies that need to be investigated further are on the inflammatory reaction at the local and systemic levels. Although the PDLSC secretome was found to be able to suppress the proinflammatory cytokine expression (tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6) and IL-1 β) of the surrounding healing tissues after 5 days of implantation in an *in vivo* periodontal defect, the findings were not statistically significant compared to the control group⁴⁵. In another study in which the PDLSC secretome was used on the spinal cord of a multiple sclerosis animal model, there was reduced expression of proinflammatory mediators (IL-17 and interferon gamma (IFN- γ))⁴⁸. Other studies that showed immunosuppression of proinflammatory cytokines in animal models include the secretome originating from human SHEDs^{40,65,43}, human DPSCs⁵² and human GMSCs⁵³. However, one study showed a contradictory finding that the DPSC secretome caused increased expression of proinflammatory cytokines such as IL-1 α , IL-6 and IL-8³⁹. To advance knowledge regarding the secretome's biocompatibility, more similar studies are needed to help with efforts to test the secretome in preclinical and clinical human studies.

Another possible reason for the lack of clinical studies would probably be the difficulty in determining the exact preparation of the secretome to be used. The preparation needs to ensure that the contents of the secretome are properly preserved with minimal protein degradation and that it has adequate shelf life. As mentioned in our results section, multiple lines of evidence were found with regard to the composition of the secretome, which includes a vast range of growth factors and cytokines⁷⁶.

The results from the proteomic analysis in this review reveal that insulin growth factor-1 (IGF-1) was found only in rat DPSC-CM⁵⁶, while no IGF-1 was detected in human DSC-CM. IGF-1 is a small peptide with 70 amino acids and has autocrine, paracrine and endocrine effects. The synthesis of IGF-1 mainly comes from the liver⁷⁷, and it is an essential mediator of cell growth, differentiation and transformation^{78,79}. The findings from this review are in line with the results from Caseiro et al., who performed a study to compare the profiles of metabolomic and bioactive factors of the human umbilical cord and DPSC secretome⁸⁰. The profiling revealed that no IGF-1 was found from the secretome analysis. The lack of IGF-1 expression in the human stem cell secretome, particularly DSC-CM, might contribute to the binding of this hormone with IGF-binding proteins (IGFBPs). IGFBP expression depends on the tissue site and developmental stage at different concentrations in different body compartments⁸¹. As shown by the results from this review, IGFBP-2, IGFBP-3, IGFBP-4 and IGFB-6 were expressed by different types of DSC-CM, such as human DPSCs, SHEDs and PDLSCs. In addition, the difference in the expression and concentration of the factors may be due to the difference in the methods used to collect the conditioned medium. The current study also found that even when the CM is derived from the same type of cells, the expression of the growth factors varied. This result may be explained by the difference in cell numbers, culture medium and condition as well their CM processing method⁸².

Apart from various growth factors and cytokines produced by the DSC secretome, this review focused on the effect of the DSC secretome on tissue regeneration. The most abundant evidence was shown in neuroregeneration studies, which was supported by the release of numerous growth factors (NGF, BDNF, NT-3, NTF, GDNF and HGF). These neurotrophins promote the differentiation and growth of neurons and are paramount in treating neurodegenerative diseases as well as neural injuries^{51 41 48 43}. Other than neuroregeneration, the DSC secretome has the potential to promote bone regeneration, probably due to the increase in the migration and mineralization potential of the surrounding osteoprogenitor cells by TGF- β 1⁸³. The TGF- β 1-BMP (bone morphogenic protein) signaling pathway has a pivotal role in osseous regeneration through the elevated expression of osteogenic genes in the targeted cells^{84,85}. This review also found the potential of DSC secretome in dentine formation for pulp protection, periodontal regeneration and other tissue regeneration, such as cartilage, salivary duct cells, liver and lung tissues, but the

mechanism of action is still inconclusive.

CONCLUSION

In conclusion, evidence showing the effectiveness of the DSC secretome in neuroregeneration and bone regeneration is encouraging. However, data from human studies are still lacking, which could impede the translation of such works into the clinical perspective. Furthermore, the potential for the secretome to be used in the regeneration of other tissue types, such as smooth and skeletal muscle, needs to be explored, as secretome content analysis has shown the presence of the relevant factors.

ABBREVIATIONS

BDNF – brain derived neurotrophic factor
 BMP – bone morphogenic protein
 CM – conditioned media
 CNTF – ciliary neurotrophic factor
 DFCs – dental follicle progenitor cells
 DPSCs – dental pulp stem cells
 DSCs – dental derived stem cells
 FGF – fibroblast growth factor
 GCSF – granulocyte colony stimulating factor
 GDNF – glial cell derived neurotrophic factor
 GMSCs – gingival tissues derived mesenchymal stem cells
 Hertwig's epithelial root sheath – HERS
 HGF – hepatocyte growth factor
 IFN- γ – interferon gamma
 IGF – insulin like growth factor
 IGF-BP – insulin like growth factor binding protein
 IL – interleukin
 MCP – monocyte chemotactic protein
 MSCs – mesenchymal stem cells
 NGF – nerve growth factor
 NT-3 – neurotrophin-3
 PAI – plasminogen activator inhibitor
 PDGFR-B – platelet derived growth factor receptor beta
 PDLSCs – periodontal ligament stem cells
 SCAPs – stem cell from apical papilla
 SDF – stromal cell derived factor
 SHEDs – stem cells from exfoliated deciduous teeth
 TGCs – tooth germ cells
 TGF- β 1 – transforming growth factor β -1
 TIMP – tissue inhibitor of metalloproteinase
 VEGF – vascular endothelial growth factor

ACKNOWLEDGMENTS

None

AUTHOR'S CONTRIBUTIONS

All authors were involved in the selection of the papers for this study. All authors read and approved the final manuscript.

FUNDING

The study was personally funded.

AVAILABILITY OF DATA AND MATERIALS

Not applicable.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

COMPETING INTERESTS

The authors declare that they have no competing interests.

REFERENCES

1. El Moshly S, Radwan IA, Rady D, Abbass MMS, El-Rashidy AA, Sadek KM, Dörfer CE, Fawzy El-Sayed KM. Dental Stem Cell-Derived Secretome/Conditioned Medium: The Future for Regenerative Therapeutic Applications. *Stem Cells Int.* 2020 Jan 31;2020:7593402;PMID: 32089709. Available from: [10.1155/2020/7593402](https://doi.org/10.1155/2020/7593402).
2. Gronthos S, Mankani M, Brahimi J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. *Proc Natl Acad Sci U S A.* 2000 Dec 5;97(25):13625-30;PMID: 11087820. Available from: [10.1073/pnas.240309797](https://doi.org/10.1073/pnas.240309797).
3. Laino G, d'Aquino R, Graziano A, Lanza V, Carinci F, Naro F, Pirozzi G, Papaccio G. A new population of human adult dental pulp stem cells: a useful source of living autologous fibrous bone tissue (LAB). *J Bone Miner Res.* 2005 Aug;20(8):1394-402;PMID: 16007337. Available from: [10.1359/JBMR.050325](https://doi.org/10.1359/JBMR.050325).
4. Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG et al. SHED: stem cells from human exfoliated deciduous teeth. *Proc Natl Acad Sci U S A.* 2003;100(10):5807-12;PMID: 12716973. Available from: <https://doi.org/10.1073/pnas.0937635100>.
5. Seo BM, Miura M, Gronthos S, Bartold PM, Batouli S, Brahimi J, Young M, Robey PG, Wang CY, Shi S. Investigation of multipotent postnatal stem cells from human periodontal ligament. *Lancet.* 2004 Jul 10;364(9429):149-55;PMID: 15246727. Available from: [10.1016/S0140-6736\(04\)16627-0](https://doi.org/10.1016/S0140-6736(04)16627-0).
6. Sonoyama W, Liu Y, Fang D, Yamaza T, Seo BM, Zhang C, Liu H, Gronthos S, Wang CY, Wang S, Shi S. Mesenchymal stem cell-mediated functional tooth regeneration in swine. *PLoS One.* 2006 Dec 20;1(1):e79;PMID: 17183711. Available from: [10.1371/journal.pone.0000079](https://doi.org/10.1371/journal.pone.0000079).
7. Sonoyama W, Liu Y, Yamaza T, Tuan RS, Wang S, Shi S, Huang GT. Characterization of the apical papilla and its residing stem cells from human immature permanent teeth: a pilot study. *J Endod.* 2008 Feb;34(2):166-71;PMID: 18215674. Available from: [10.1016/j.joen.2007.11.021](https://doi.org/10.1016/j.joen.2007.11.021).
8. Morsczeck C, Götz W, Schierholz J, Zeilhofer F, Kühn U, Möhl C, Sippel C, Hoffmann KH. Isolation of precursor cells (PCs) from human dental follicle of wisdom teeth. *Matrix Biol.* 2005 Apr;24(2):155-65;.

9. Tang L, Li N, Xie H, Jin Y. Characterization of mesenchymal stem cells from human normal and hyperplastic gingiva. *Journal of cellular physiology*. 2011;226(3):832–842.
10. Tomar GB, Srivastava RK, Gupta N, Barhanpurkar AP, Pote ST, Jhaveri HM, et al. Human gingiva-derived mesenchymal stem cells are superior to bone marrow-derived mesenchymal stem cells for cell therapy in regenerative medicine. *Biochemical and biophysical research communications*. 2010;393(3):377–383.
11. Lo Monaco M, Gervois P, Beaumont J, Clegg P, Bronckaers A, Vandeweerdt JM et al. Therapeutic potential of dental pulp stem cells and leukocyte- and platelet-rich fibrin for osteoarthritis. *Cells*. 2020;9(4);PMID: 32326610. Available from: <https://doi.org/10.3390/cells9040980>.
12. Travess H, Robert-Harry D, SJ. Orthodontics. Part 8: Extraction in orthodontics. *Br Dent J*. 2004;4(196):195–203;PMID: 15039723. Available from: <https://doi.org/10.1038/sj.bdj.4810979>.
13. Kim SJ, Hwang CJ, Park JH, Kim HJ, Yu H. Surgical removal of asymptomatic impacted third molars: considerations for orthodontists and oral surgeons. *Semin Orthod*. 2016;22(1):75–83;Available from: <https://doi.org/10.1053/j.sodo.2015.10.010>.
14. Lindqvist B, Thilander B. Extraction of third molars in cases of anticipated crowding in the lower jaw. *Am J Orthod*. 1982;81(2):130–9;Available from: [https://doi.org/10.1016/0002-9416\(82\)90037-9](https://doi.org/10.1016/0002-9416(82)90037-9).
15. Choi YJ, Lee JS, Cha JY, Park YC. Total distalization of the maxillary arch in a patient with skeletal Class II malocclusion. *Am J Orthod Dentofacial Orthop*. 2011;139(6):823–33;PMID: 21640890. Available from: <https://doi.org/10.1016/j.ajodo.2009.07.026>.
16. Verweij JP, Mensink G, Fiocco M, van Merkesteyn JP. Presence of mandibular third molars during bilateral sagittal split osteotomy increases the possibility of bad split but not the risk of other post-operative complications. *J Craniomaxillofac Surg*. 2014 Oct;42(7):e359–63.
17. Yoshida T, Washio K, Iwata T, Okano T, Ishikawa I. Current status and future development of cell transplantation therapy for periodontal tissue regeneration. *Int J Dent*. 2012;2012:307024.
18. Daneshmandi L, Shah S, Jafari T, Bhattacharjee M, Momah D, Saveh-Shemshaki N, Lo KW, Laurencin CT. Emergence of the Stem Cell Secretome in Regenerative Engineering. *Trends Biotechnol*. 2020 Dec;38(12):1373–1384;PMID: 32622558. Available from: [10.1016/j.tibtech.2020.04.013](https://doi.org/10.1016/j.tibtech.2020.04.013).
19. Baraniak PR, McDevitt TC. Paracrine actions in stem cells and tissue regeneration. *Regen Med*. 2010;5(1):121–43.
20. Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. *International journal of molecular sciences*. 2017;18(9):1852.
21. Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. *Experimental neurology*. 2006;198(1):54–64.
22. Majumdar MK, Banks V, Peluso DP, Morris EA. Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cells. *Journal of Cellular Physiology*. 2000;185(1):98–106.
23. Wada N, Menicanin D, Shi S, Bartold PM, Gronthos S. Immunomodulatory properties of human periodontal ligament stem cells. *Journal of cellular physiology*. 2009;219(3):667–676.
24. Osugi M, Katagiri W, Yoshimi R, Inukai T, Hibi H, Ueda M. Conditioned media from mesenchymal stem cells enhanced bone regeneration in rat calvarial bone defects. *Tissue engineering part A*. 2012;18(13–14):1479–1489.
25. Kaigler D, Krebsbach PH, Polverini PJ, Mooney DJ. Role of vascular endothelial growth factor in bone marrow stromal cell modulation of endothelial cells. *Tissue engineering*. 2003;9(1):95–103.
26. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. *Journal of cellular physiology*. 2007;213(2):341–347.
27. Shimojima C, Takeuchi H, Jin S, Parajuli B, Hattori H, Suzumura A, et al. Conditioned medium from the stem cells of human exfoliated deciduous teeth ameliorates experimental autoimmune encephalomyelitis. *The Journal of Immunology*. 2016;196(10):4164–4171.
28. Xia Y, Tang HN, Wu RX, Yu Y, Gao LN, Chen FM. Cell responses to conditioned media produced by patient-matched stem cells derived from healthy and inflamed periodontal ligament tissues. *Journal of periodontology*. 2016;87(5):e53–e63.
29. Bermudez MA, Sendon-Lago J, Eiro N, Trevino M, Gonzalez F, Yebra-Pimentel E, et al. Corneal epithelial wound healing and bactericidal effect of conditioned medium from human uterine cervical stem cells. *Investigative ophthalmology & visual science*. 2015;56(2):983–992.
30. Bermudez MA, Sendon-Lago J, Seoane S, Eiro N, Gonzalez F, Saa J, et al. Anti-inflammatory effect of conditioned medium from human uterine cervical stem cells in uveitis. *Experimental Eye Research*. 2016;149:84–92.
31. Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. *PLOS Med*. 2009, July;6(7);PMID: 19621072. Available from: <https://doi.org/10.1371/journal.pmed.1000097>.
32. Yang ZH, Zhang XJ, Dang NN, Ma ZF, Xu L, Wu JJ et al. Apical tooth germ cell-conditioned medium enhances the differentiation of periodontal ligament stem cells into cementum/periodontal ligament-like tissues. *J Periodont Res*. 2009;44(2):199–210;PMID: 18624943. Available from: <https://doi.org/10.1111/j.1600-0765.2008.01106.x>.
33. Aranha AMF, Zhang Z, Neiva KG, Costa CAS, Hebling J, Nör JE. Hypoxia enhances the angiogenic potential of human dental pulp cells. *J Endod*. 2010;36(10):1633–7;PMID: 20850667. Available from: <https://doi.org/10.1016/j.joen.2010.05.013>.
34. Huo N, Tang L, Yang Z, Qian H, Wang Y, Han C et al. Differentiation of dermal multipotent cells into odontogenic lineage induced by embryonic and neonatal tooth germ cell-conditioned medium. *Stem Cells Dev*. 2010;19(1):93–104;PMID: 19469666. Available from: <https://doi.org/10.1089/scd.2009.0048>.
35. Wen X, Nie X, Zhang L, Liu L, Deng M. Adipose tissue-deprived stem cells acquire cementoblast features treated with dental follicle cell conditioned medium containing dentin non-collagenous proteins in vitro. *Biochem Biophys Res Commun*. 2011;409(3):583–9;PMID: 21619870. Available from: <https://doi.org/10.1016/j.bbrc.2011.05.067>.
36. Wang YX, Ma ZF, Huo N, Tang L, Han C, Duan YZ et al. Porcine tooth germ cell conditioned medium can induce odontogenic differentiation of human dental pulp stem cells. *J Tissue Eng Regen Med*. 2011;5(5):354–62;PMID: 20799278. Available from: <https://doi.org/10.1002/term.321>.
37. Murakami M, Horibe H, Iohara K, Hayashi Y, Osako Y, Takei Y et al. The use of granulocyte-colony stimulating factor induced mobilization for isolation of dental pulp stem cells with high regenerative potential. *Biomaterials*. 2013;34(36):9036–47;PMID: 23988014. Available from: <https://doi.org/10.1016/j.biomaterials.2013.08.011>.
38. Liu N, Gu B, Liu N, Nie X, Zhang B, Zhou X et al. Wnt/ β -catenin pathway regulates cementogenic differentiation of adipose tissue-deprived stem cells in dental follicle cell-conditioned medium. *PLOS ONE*. 2014;9(5):e93364;PMID: 24806734. Available from: <https://doi.org/10.1371/journal.pone.0093364>.
39. Hayashi Y, Murakami M, Kawamura R, Ishizaka R, Fukuta O, Nakashima M. CXCL14 and MCP1 are potent trophic factors associated with cell migration and angiogenesis leading to higher regenerative potential of dental pulp side population cells. *Stem Cell Res Ther*. 2015;6(1):111;PMID: 26021377. Available from: <https://doi.org/10.1186/s13287-015-0088-z>.

40. Wakayama H, Hashimoto N, Matsushita Y, Matsubara K, Yamamoto N, Hasegawa Y et al. Factors secreted from dental pulp stem cells show multifaceted benefits for treating acute lung injury in mice. *Cytotherapy*. 2015;17(8):1119-29;PMID: 26031744. Available from: <https://doi.org/10.1016/j.jcyt.2015.04.009>.
41. Mita T, Furukawa-Hibi Y, Takeuchi H, Hattori H, Yamada K, Hibi H et al. Conditioned medium from the stem cells of human dental pulp improves cognitive function in a mouse model of Alzheimer's disease. *Behav Brain Res*. 2015;293:189-97;PMID: 26210934. Available from: <https://doi.org/10.1016/j.bbr.2015.07.043>.
42. Murakami M, Hayashi Y, Iohara K, Osako Y, Hirose Y, Nakashima M. Tropic effects and regenerative potential of mobilized mesenchymal stem cells from bone marrow and adipose tissue as alternative cell sources for pulp/dentin regeneration. *Cell Transplant*. 2015;24(9):1753-65;PMID: 25199044. Available from: <https://doi.org/10.3727/096368914X683502>.
43. Sugimura-Wakayama Y, Katagiri W, Osugi M, Kawai T, Ogata K, Sakaguchi K et al. Peripheral nerve regeneration by secretomes of stem cells from human exfoliated deciduous teeth. *Stem Cells Dev*. 2015;24(22):2687-99;PMID: 26154068. Available from: <https://doi.org/10.1089/scd.2015.0104>.
44. Kawamura R, Hayashi Y, Murakami H, Nakashima M. EDTA soluble chemical components and the conditioned medium from mobilized dental pulp stem cells contain an inductive microenvironment, promoting cell proliferation, migration, and odontoblastic differentiation. *Stem Cell Res Ther*. 2016;7(1):77;PMID: 27387974. Available from: <https://doi.org/10.1186/s13287-016-0334-z>.
45. Nagata M, Iwasaki K, Akazawa K, Komaki M, Yokoyama N, Izumi Y et al. Conditioned medium from periodontal ligament stem cells enhances periodontal regeneration. *Tissue Eng Part A*. 2017;23(9-10):367-77;PMID: 28027709. Available from: <https://doi.org/10.1089/ten.tea.2016.0274>.
46. Yamamoto T, Osako Y, Ito M, Murakami M, Hayashi Y, Horibe H et al. Tropic effects of dental pulp stem cells on Schwann cells in peripheral nerve regeneration. *Cell Transplant*. 2016;25(1):183-93;PMID: 25903498. Available from: <https://doi.org/10.3727/096368915X688074>.
47. Fujio M, Xing Z, Sharabi N, Xue Y, Yamamoto A, Hibi H et al. Conditioned media from hypoxic-cultured human dental pulp cells promotes bone healing during distraction osteogenesis. *J Tissue Eng Regen Med*. 2017;11(7):2116-26;PMID: 26612624. Available from: <https://doi.org/10.1002/term.2109>.
48. Giacoppo S, Thangavelu SR, Diomedea F, Bramanti P, Conti P, Trubiani O et al. Anti-inflammatory effects of hypoxia-preconditioned human periodontal ligament cell secretome in an experimental model of multiple sclerosis: a key role of IL-37. *FASEB J*. 2017;31(12):5592-608;PMID: 28842429. Available from: <https://doi.org/10.1096/fj.201700524R>.
49. Kano F, Matsubara K, Ueda M, Hibi H, Yamamoto A. Secreted ectodomain of sialic acid-binding Ig-like Lectin-9 and monocyte chemoattractant Protein-1 synergistically regenerate transected rat peripheral nerves by altering macrophage polarity. *Stem Cells*. 2017;35(3):641-53;PMID: 27862629. Available from: <https://doi.org/10.1002/stem.2534>.
50. Kolar MK, Itte VN, Kingham PJ, Novikov LN, Wiberg M, Kelk P. The neurotrophic effects of different human dental mesenchymal stem cells. *Sci Rep*. 2017;7(1):12605;PMID: 28974767. Available from: <https://doi.org/10.1038/s41598-017-12969-1>.
51. Kumar A, Kumar V, Rattan V, Jha V, Bhattacharyya S. Secretome cues modulate the neurogenic potential of bone marrow and dental stem cells. *Mol Neurobiol*. 2017;54(6):4672-82;PMID: 27422132. Available from: <https://doi.org/10.1007/s12035-016-0011-3>.
52. Nakayama H, Iohara K, Hayashi Y, Okuwa Y, Kurita K, Nakashima M. Enhanced regeneration potential of mobilized dental pulp stem cells from immature teeth. *Oral Dis*. 2017;23(5):620-8;PMID: 27973697. Available from: <https://doi.org/10.1111/odi.12619>.
53. Rajan TS, Diomedea F, Bramanti P, Trubiani O, Mazzon E. Conditioned medium from human gingival mesenchymal stem cells protects motor-neuron-like NSC-34 cells against scratch-injury-induced cell death. *Int J Immunopathol Pharmacol*. 2017;30(4):383-94;PMID: 29140156. Available from: <https://doi.org/10.1177/0394632017740976>.
54. Gharraei MA, Xue Y, Mustafa K, Lie SA, Fristad I. Human dental pulp stromal cell conditioned medium alters endothelial cell behavior. *Stem Cell Res Ther*. 2018;9(1):69;PMID: 29562913. Available from: <https://doi.org/10.1186/s13287-018-0815-3>.
55. Tsuruta T, Sakai K, Watanabe J, Katagiri W, Hibi H. Dental pulp-derived stem cell conditioned medium to regenerate peripheral nerves in a novel animal model of dysphagia. *PLOS ONE*. 2018;13(12):e0208938;PMID: 30533035. Available from: <https://doi.org/10.1371/journal.pone.0208938>.
56. Chen TF, Chen KW, Chien Y, Lai YH, Hsieh ST, Ma HY et al. Dental pulp stem cell-derived factors alleviate subarachnoid hemorrhage-induced neuroinflammation and ischemic neurological deficits. *Int J Mol Sci*. 2019;20(15):.
57. Cara SPHM, Origassa CST, de Sá Silva F, Moreira MSNAA, de Almeida DC, Pedroni ACF et al. Angiogenic properties of dental pulp stem cells conditioned medium on endothelial cells in vitro and in rodent orthotopic dental pulp regeneration. *Heliyon*. 2019;5(4):e01560;PMID: 31183428. Available from: <https://doi.org/10.1016/j.heliyon.2019.e01560>.
58. Gervois P, Ratajczak J, Wolfs E, Vanganswinkel T, Dillen Y, Merckx G et al. Preconditioning of human dental pulp stem cells with leukocyte- and platelet-rich fibrin-derived factors does not enhance their neuroregenerative effect. *Stem Cells Int*. 2019;2019:8589149;PMID: 31089335. Available from: <https://doi.org/10.1155/2019/8589149>.
59. Miura-Yura E, Tsunekawa S, Naruse K, Nakamura N, Motegi M, Nakai-Shimoda H et al. Secreted factors from cultured dental pulp stem cells promoted neurite outgrowth of dorsal root ganglion neurons and ameliorated neural functions in streptozotocin-induced diabetic mice. *J Diabetes Investig*. 2020;11(1):28-38;PMID: 31144464. Available from: <https://doi.org/10.1111/jdi.13085>.
60. Aghamohammadi Z, Kadkhodazadeh M, Torshabi M, Tabatabaei F. A compound of concentrated growth factor and periodontal ligament stem cell-derived conditioned medium. *Tissue Cell*. 2020;65:101373;PMID: 32746991. Available from: <https://doi.org/10.1016/j.tice.2020.101373>.
61. Chen YR, Lai PL, Chien Y, Lee PH, Lai YH, Ma HI et al. Improvement of impaired motor functions by human dental exfoliated deciduous teeth stem cell-derived factors in a rat model of Parkinson's disease. *Int J Mol Sci*. 2020;21(11);PMID: 32471263. Available from: <https://doi.org/10.3390/ijms21113807>.
62. Hiraki T, Kunimatsu R, Nakajima K, Abe T, Yamada S, Rikitake K et al. Stem cell-derived conditioned media from human exfoliated deciduous teeth promote bone regeneration. *Oral Dis*. 2020;26(2):381-90;PMID: 31808229. Available from: <https://doi.org/10.1111/odi.13244>.
63. Hong H, Chen X, Li K, Wang N, Li M, Yang B et al. Dental follicle stem cells rescue the regenerative capacity of inflamed rat dental pulp through a paracrine pathway. *Stem Cell Res Ther*. 2020;11(1):333;PMID: 32746910. Available from: <https://doi.org/10.1186/s13287-020-01841-1>.
64. Muhammad SA, Nordin N, Hussin P, Mehat MZ, Abu Kasim NHA, Fakurazi S. Protective effects of stem cells from human exfoliated deciduous teeth derived conditioned medium on osteoarthritic chondrocytes. *PLOS ONE*. 2020;15(9) (september 9):e0238449;PMID: 32886713. Available from: <https://doi.org/10.1371/journal.pone.0238449>.
65. Ogasawara N, Kano F, Hashimoto N, Mori H, Liu Y, Xia L et al. Factors secreted from dental pulp stem cells show multifaceted benefits for treating experimental temporomandibular joint osteoarthritis. *Osteoarthr Cartil*. 2020;28(6):831-41;PMID: 32272195. Available from: <https://doi.org/10.1016/j.joca.2020.03.010>.

66. Qiu J, Wang X, Zhou H, Zhang C, Wang Y, Huang J et al. Enhancement of periodontal tissue regeneration by conditioned media from gingiva-derived or periodontal ligament-derived mesenchymal stem cells: a comparative study in rats. *Stem Cell Res Ther.* 2020;11(1):42;PMID: 32014015. Available from: <https://doi.org/10.1186/s13287-019-1546-9>.
67. Takeuchi H, Takahashi H, Tanaka A. Effects of human dental pulp stem cell-derived conditioned medium on atrophied submandibular gland after the release from ligation of the main excretory duct in mice. *J Hard Tissue Biol.* 2020;29(3):183-92; Available from: <https://doi.org/10.2485/jhtb.29.183>.
68. Yang H, Li G, Han N, Zhang X, Cao YYY, Cao YYY et al. Secreted frizzled-related protein 2 promotes the osteo/odontogenic differentiation and paracrine potentials of stem cells from apical papilla under inflammation and hypoxia conditions. *Cell Prolif.* 2020;53(1):e12694;PMID: 31568642. Available from: <https://doi.org/10.1111/cpr.12694>.
69. Mao Zheng J, Yuan Kong Y, Yin Li Y, Zhang W. MagT1 regulated the odontogenic differentiation of BMSCs induced by TGF- β 1 via ERK signaling pathway. *Stem cell research & therapy.* 2019;10(1):1-13.
70. Aloe L, Rocco ML, Bianchi P, Manni L. Nerve growth factor: from the early discoveries to the potential clinical use. *J Transl Med.* 2012;10:239;PMID: 23190582. Available from: <https://doi.org/10.1186/1479-5876-10-239>.
71. Bathina S, Das UN. Paperbrain-derived neurotrophic factor and its clinical implications. *Arch Med Sci.* 2015;11(6):1164-78. doi: 10.5114/aoms.2015.56342, PMID 26788077. ;PMID: 26788077. Available from: <https://doi.org/10.5114/aoms.2015.56342>.
72. Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM et al. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. *Science.* 1990;247(4949 Pt 1):1446-51;PMID: 2321006. Available from: <https://doi.org/10.1126/science.247.4949.1446>.
73. Zeitlin BD. Banking on teeth - stem cells and the dental office. *Biomed J.* 2020;43(2):124-33;PMID: 32381462. Available from: <https://doi.org/10.1016/j.bj.2020.02.003>.
74. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy.* 2006;8(4):315-7;PMID: 16923606. Available from: <https://doi.org/10.1080/14653240600855905>.
75. Teixeira FG, Salgado AJ. Mesenchymal stem cells secretome: current trends and future challenges. *Neural Regen Res.* 2020;15(1):75-7;PMID: 31535654. Available from: <https://doi.org/10.4103/1673-5374.264455>.
76. Pawitan JA. Prospect of stem cell conditioned medium in regenerative medicine. *BioMed Res Int.* 2014;2014:965849;PMID: 25530971. Available from: <https://doi.org/10.1155/2014/965849>.
77. Troncoso R, Ibarra C, Vicencio JM, Jaimovich E, Lavandero S. New insights into IGF-1 signaling in the heart. *Trends Endocrinol Metab.* 2014, March 1;25(3):128-37;PMID: 24380833. Available from: <https://doi.org/10.1016/j.tem.2013.12.002>.
78. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. *Arterioscler Thromb Vasc Biol.* 2004, March 1;24(3):435-44;PMID: 14604834. Available from: <https://doi.org/10.1161/01.ATV.0000105902.89459.09>.
79. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. *Cardiovasc Res.* 1995;30(6):825-34;PMID: 7534704. Available from: <https://doi.org/10.1210/endo.136.4.7534704>.
80. Caseiro AR, Santos Pedrosa S, Ivanova G, Vieira Branquinho M, Almeida A, Faria F et al. Mesenchymal Stem/ stromal Cells metabolomic and bioactive factors profiles: A comparative analysis on the umbilical cord and dental pulp derived Stem/ stromal Cells secretome. *PLOS ONE.* 2019;14(11):e0221378;PMID: 31774816. Available from: <https://doi.org/10.1371/journal.pone.0221378>.
81. Schneider MR, Lahm H, Wu M, Hoefflich A, Wolf E. Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins. *FASEB J.* 2000;14(5):629-40;PMID: 10744620. Available from: <https://doi.org/10.1096/fasebj.14.5.629>.
82. Cho YJ, Song HS, Bhang S, Lee S, Kang BG, Lee JC et al. Therapeutic effects of human adipose stem cell-conditioned medium on stroke. *J Neurosci Res.* 2012;90(9):1794-802;PMID: 22535477. Available from: <https://doi.org/10.1002/jnr.23063>.
83. Paschalidis T, Bakopoulou A, Papa P, Leyhausen G, Geurtsen W, Koidis P. Dental pulp stem cells' secretome enhances pulp repair processes and compensates TEGDMA-induced cytotoxicity. *Dent Mater.* 2014;30(12):e405-18;PMID: 25241918. Available from: <https://doi.org/10.1016/j.dental.2014.08.377>.
84. Diomedea F, D'Aurora M, Gugliandolo A, Merciaro I, Ettore V, Bramanti A et al. A novel role in skeletal segment regeneration of extracellular vesicles released from periodontal-ligament stem cells. *Int J Nanomedicine.* 2018;13:3805-25;PMID: 29988728. Available from: <https://doi.org/10.2147/IJN.S162836>.
85. Pizzicannella J, Gugliandolo A, Orsini T, Fontana A, Ventrella A, Mazzon E et al. Engineered extracellular vesicles from human periodontal-ligament stem cells increase VEGF/VEGFR2 expression during bone regeneration. *Front Physiol.* 2019;10(APR):512;PMID: 31114512. Available from: <https://doi.org/10.3389/fphys.2019.00512>.